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Abstract  
Background: The 5’-noncoding region (5’NCR) of the HCV genome 
comprises an internal ribosome entry site essential for HCV-
translation/replication. Phosphorothioate oligodeoxynucleotides (tS-
ODN) complementary to this region have been shown to inhibit HCV-
translation in vitro. Thus, in this study, bile acid conjugated tS-ODN 
were generated to increase cell-selective and specific inhibition of 
5’NCR-dependent HCV translation. 
Methods: Different bile acid conjugated tS-ODN complementary to the 
HCV5’NCR were generated and selected for their inhibitory potential in 
an in vitro transcription/translation assay. An adenovirus encoding the 
HCV5’NCR fused to the luciferase gene (Ad-GFP-NCRluc) was 
generated to quantify 5’NCR-dependent HCV gene expression in cell 
culture and in vivo. The hepatoma cells HepG2 and CCL13 were stably 
transfected with the OATP1B1 transporter to analyze OATP-selective 
uptake of FITC-marked bile acid conjugated ODN by flow cytometry.  
Results: In the in vitro transcription/translation assay, a 17mer 
taurocholate conjugated ODN (tS-ODN4_13T) showed the best 
inhibition of 5’NCR-dependent HCV translation. The inhibitory capacity 
of the selected 17mer antisense sequence was confirmed in Huh7 cells 
containing the HCV subgenomic replicon. In OATP1B1-expressing 
HepG2 or CCL13 cells, which were transduced with Ad-GFP-NCRluc,  
tS-ODN4_13T treatment significantly reduced 5’NCR-dependent 
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luciferase expression compared to the mismatch-ODN by 70% and 
57%, respectively. In vivo, bile acid conjugated ODN also showed a 
trend to block 5’NCR-dependent HCV gene expression by 40%. Flow 
cytometry revealed an approx. two-fold increase of enhanced uptake of 
FITC-conjugated-tS-ODN4_13T in OATP1B1-HepG2 cells compared to 
parental HepG2 cells. Moreover, FITC-taurocholate conjugated tS-
ODN were not taken up by non-hepatic cells, suggesting selective ODN 
entry into liver-derived cells.  
Conclusions: Bile acid conjugation with taurocholate can increase 
selective ODN uptake by liver-derived cells through OATP transports, 
enhancing the specific inhibition of the HCV gene expression in 
different test systems. Thus, this approach may represent a new 
strategy for the selective control of HCV due to antisense ODN. 
 
Summary ‘box’ 
What is already known about this subject? 
- Hepatitis C virus (HCV) is a major cause for chronic liver disease, 
cirrhosis and hepatocellular carcinoma, but current standard therapy 
remains unsatisfactory. 
- The 5’-noncoding region (5’NCR) of the HCV genome comprises an 
internal ribosome entry site which is essential for HCV 
translation/replication. 
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- Antisense based strategies, such as phosphorothioate 
oligodeoxynucleotide (tS-ODN), complementary to the HCV5’NCR 
have been shown to inhibit HCV translation in vitro. 
- However, major obstacles in the therapeutic application of antisense 
nucleotides are poor tissue delivery and cell membrane transport.   
 
What are the new findings? 
- A 17mer ODN sequence complementary to HCV5’NCR is able to 
inhibit 5’NCR-dependent HCV-translation in an in vitro 
transcription/translation test system by more than 90% and it is also  
effective  in Huh7 cells containing the HCV subgenomic replicon. 
- Conjugation of this 17mer phosphorothioate modified 
oligodeoxynucleotide to taurocholate significantly increases selective 
ODN uptake by OATP (organic anion transporting polypeptides) 
expressing liver-derived cells without transfection reagent. 
- Taurocholate conjugated antisense tS-ODN with the 17mer sequence 
complementary to HCV5’NCR results in a specific and more effective 
inhibition of HCV gene expression in OATP-expressing liver-derived 
cells than unconjugated tS-ODN in cell culture and in vivo. 
 
How might it impact on clinical practice in the foreseeable future? 
- Taurocholate conjugated antisense ODN is a novel approach to 
improve delivery and efficacy of antisense nucleotides into the liver. 
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The tested taurocholate conjugated 17mer antisense ODN 
complementary to HCV5’NCV represents a promising strategy for the 
control of hepatitis C infection. It should be tested for its inhibitory 
effects in patients with chronic hepatitis C. 
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Introduction 
Hepatitis C virus (HCV) is a major cause of liver disease, affecting over 
200 million patients worldwide. Despite progress in HCV treatment, the 
overall response of a combined therapy with ribavirin and pegylated 
interferonα in patients with HCV genotype 1 or 4 remains unsatisfactory 
(1). Novel compounds against HCV-NS3 protease or HCV-NS5B RNA 
have been developed in recent years showing high antiviral activity (2). 
However, rapid HCV drug resistance to these agents considerably 
limits their efficacy. Thus, development of novel therapeutic strategies 
is called for.  
HCV is a positive-strand RNA virus of approximately 9,600 nucleotides 
(nt). HCV isolates show a considerable sequence diversity leading to 
subdivision into six HCV genotypes (3, 4). At the 5’-end, the HCV 
genome contains a noncoding region (5’NCR) of 341nt, which is the 
most highly conserved region among all HCV strains (5, 6). It forms a 
stable secondary structure which contains an internal ribosome entry 
site (IRES) necessary for HCV translation/replication, representing an 
ideal target for antisense approaches.  
In fact, we and others showed that phosphorothioate modified 
antisense oligodeoxynucleotides (ODN), RNA interference (siRNA), 
antisense RNA or hammerhead ribozymes complementary to this 
region can effectively inhibit HCV translation (7-11). 
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However, poor specific tissue delivery and the transport through cell 
membranes are major obstacles in the therapeutic application of 
antisense nucleotides (12). Various strategies using liposomes, 
nanoparticles, cholesterol conjugates or cell-penetrating peptides have 
been developed to enhance ODN or siRNA delivery. However, their 
tissue specificity and use in vivo remain significantly limited (13-16). 
Two different transport systems are involved in the uptake of bile acids 
of hepatocytes: the Na+-taurocholate-cotransporting polypeptide 
(NTCP) and several multispecific organic anion transporting 
polypeptides (OATPs) (17-19). Conjugation of several therapeutic 
drugs to bile acids has been shown to increase uptake into hepatoma 
cells via these transport systems (20, 21). Thus, conjugation of ODN to 
bile acids may also increase a liver-specific and more effective 
inhibition of HCV translation of antisense ODN.  
In this study, conjugation of phosphorothioate-modified antisense 
oligonucleotides to taurocholate allowed selective ODN uptake in liver-
derived cells and effective inhibition of HCV translation in different test 
systems, pointing to a promising new approach in the control of HCV 
infection. 
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Material and Methods 
Chemical synthesis of bile acid conjugated oligonucleotides 
(ODN).  
Starting from the previously described phosphorothioate modified 
23mer ODN complementary to the nucleotides 326-348 of HCV5’NCR 
(tS-ODN4), which was identified as a potent inhibitor of the HCV 
translation (10), several shortened antisense ODN were generated for 
subsequent bile acid conjugation (Tab.1).  
tS-ODN4 5’-T GCT CAT GGT GCA CGG TCT ACG A-3’ 23mer 
tS-ODN4_11          5’-T CAT GGT GCA CGG TCT ACG A-3’ 20mer 
tS-ODN4_13                  5’-T GGT GCA CGG TCT ACG A-3’ 17mer 
tS-ODN4_26          5’-T CAT GGT GCA CGG T-3’ 14mer 
tS-ODN4_27          5’-T CAT GGT GCA C-3’ 11mer 
tS-ODN4_28          5’-T CAT GGT G-3’ 08mer 
tS-ODN4_30       5’-CT CAT GGT-3’ 08mer 
tS-ODN4_31    5’-GCT CAT GG-3’ 08mer 
tS-ODN4_33 5’-T GCT CAT G-3’ 08mer 
tS-ODN4_34                5’-AT GGT GCA-3’ 08mer 
Tab.1. Shortened ODN derived of tS-ODN4 (23mer) complementary to HCVRNA 
nucleotides 326-348. t: terminally-modified; S: phosphorothioate; nucleotides flanking 
the modified phosphate in 3’ direction are in bold. 
 
After testing their inhibitory capacity, tS-ODN4_13 was chosen for 
conjugation to cholate (C), taurocholate (T) or cholesterol (X) as 
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described previously (22), (Fig. 1A). Briefly, synthesis of cholic and 
taurocholic acid phosphoramidites started from commercially available 
cholic acid. In a sequence of seven reaction steps, 3α-(2-
hydroxyethoxy)cholic acid could be obtained. The 2-hydroxyethoxy 
linker was introduced at the 3α-hydroxyl group, where it has least 
influence on substrate recognition by hepatic bile acid transporters 
(23). The analogous taurocholic acid phosphoramidite starting from 3α-
(2-hydroxyethoxy)cholic acid was achieved via an amidation reaction 
with 2-aminoethane-ethyl-sulfonate. ODN synthesis was carried out on 
a PerSeptive Biosystems DNA synthesizer. To increase the nuclease 
stability of ODN, thioate modifications were introduced at three 
phosphodiesters at each end. In several control ODN, fluorescein 
isothiocyanat (FITC) was covalently attached to the ODN at the 3´-
position. ODN were purified by RP-HPLC. FITC-labeled ODN were 
additionally purified by preparative polyacrylamide gel electrophoresis. 
All compounds were characterized by analytical RP-HPLC, analytical 
PAGE and electrospray ionization mass spectrometry(24). 
 
Cell lines. 911 cells are human embryonic retinoblasts used to 
propagate E1-deleted adenoviruses (25). The human hepatoma cells 
HepG2 (ATCC HB8065) and CCL13 (ATCC CCL-13) were stably 
transfected with the OATP1B1 transporter to study selective delivery of 
bile acid conjugated ODN.  The previously described Huh7 cell clone 
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Con1/Luc-ubi-neo/ET containing the HCV subgenomic replicon of 
genotype 1b was used for inhibition experiments (26). Kidney-derived 
cells HEK-293 (ATCC CRL-1573) and colorectal adenocarcinoma cells  
HT29 (ATCC HTB-38) served as control. Cells were maintained in 
Dulbecco’s modified Eagle’s medium with 10% fetal calf serum (Life 
Technologies, Karlsruhe, Germany), 100 units/ml of penicillin and 100 
µg/ml of streptomycin (Sigma, Taufkirchen, Germany). The stable 
transfected cells and the cell clones containing the HCV replicon were 
selected with neomycin (PAA, Cölbe, Germany).  
 
Plasmids. Plasmids pCMVNCRluc and pT7NCRluc contain 
HCV5’NCR and the first 66 nt of the core gene fused in frame to the 
firefly luciferase sequence and have been previously described (10).  
The adenoviral backbone vector pAdEasy-1 and the transfer vector 
pAdTrackCMV, which possesses a GFP-gene, kindly provided by Dr. 
B. Vogelstein, University of Baltimore, USA (27), were used to generate 
replication-deficient adenoviruses. Full-length OATP1B1-cDNA was 
isolated from a human liver Rapid-Screen library panel (OriGene 
Technologies) and cloned into the plasmid pCMV6-XL4 as described 
previously (28). OATP1B1-cDNA was cut out of pCMV6-XL4 and 
cloned into the expression vector pcDNA3.1/V5-His (Invitrogen, 
Karlsruhe, Germany) to generate pcDNA3.1/V5-His-OATP1B1.  
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In vitro transcription/translation assay. The in vitro 
transcription/translation test system has been described previously 
(10). Briefly, 1 µg of linearized pT7NCRluc was incubated with T7RNA-
Polymerase (Promega, Mannheim, Germany) at 37°C for 1 h. 50ng of 
DNA-free RNA was used for translation into a commercially available 
rabbit reticulocyte lysate according to the manufacturer’s instructions 
(Promega). ODN were added to the translation mixture and incubated 
at 75°C for 10 min and allowed to cool at room temperature for 1 h. 
Next, luciferase assay was performed. 
 
Construction of adenoviral plasmids and production of virus 
stocks. The HCV-luciferase sequence NCRluc was cut from 
pCMVNCRluc and cloned into pAdTrackCMV. The generated plasmid 
pAdTrackCMV-NCRluc was recombined with pAdEasy-1 according to 
the published protocol by He et al. (27). Finally, recombinant plasmids 
were transfected into 911 cells to generate Ad-GFP-NCRluc viruses 
(Fig. 1B).  
 
Generation of stably OATP1B1-transfected cells. Stable 
transfections were performed with lipofectamine according to the 
manufacturer’s instructions. Briefly, HepG2 cells and CCL13 cells were 
grown up to a 90% confluence. 20 µg pcDNA3.1/V5-His-OATP1B1 was 
mixed with 20 µl lipofectamine and FCS-free medium (Optimem, 
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Invitrogen) and incubated for 45 min. Lipofectamine/DNA mixture was 
added to the cells for 4 h. 72 h later cells were cultured under G418 
selection (800 µg/ml) for four weeks.  
 
Polymerase chain reaction (PCR). To demonstrate 5’NCR 
transcription in HepG2-OATP1B1 and CCL13-OATP1B1 cells after 
transduction with Ad-GFP-NCRluc, total cellular RNA was isolated with 
the RNA Isolation Kit (Sigma, Taufkirchen, Germany) according to the 
manufacturer’s instructions. PCR was performed using the following 
primers: forward, HCV5´NCR 5‘-GCTCTAGACCCAAGCTTGCCAGCC-
3‘ and reverse, HCV5´NCR 5‘-GGCCGGTACCGACGTCCTGTGGG-3‘. 
1 µg of DNA-free RNA was mixed with the primers and denatured at 
75°C for 10 min. Subsequently,  reverse transcription was performed at 
37°C for 1 h. Generated cDNA served as template for the amplification 
reaction. 
To confirm OATP1B1 transcription, total cellular RNA was isolated from 
stable transfected HepG2-OATP1B1 and CCL13-OATP1B1 cultures. 
The following primers, corresponding to bp 1188-1211 and 1664-1688 
of the OATP1B1 cDNA, were used for reverse transcription: forward, 
5’-AGAGCAACAGTATGGTCAGCCTTC-3’ and reverse, 5’-
AAGCATCATCTCTTGGGCATTCAC-3’. 50 ng of RNA were reverse 
transcribed, followed by PCR amplification as described above. 
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Protein extraction and luciferase assay. Cells were solubilized in 
lysis buffer (25 mM Tris-H3PO4, 2 mM CDTA, 10%DTT and 1%Triton 
X-100). Lysates were cleared by centrifugation, and protein 
concentration was determined with the Bradford protein assay (BioRad, 
Munich, Germany) according to the manufacturer’s instructions. 
Luciferase activity was determined with the Luciferase Reporter 
System (Promega, Mannheim, Germany) according to the 
manufacturer’s instructions. The relative light units (RLU) were 
measured during 30 sec in a luminometer (Berthold, Pforzheim, 
Germany).  
 
Western blot analysis of OATP1B1 expression in hepatoma cells. 
Expression of OATP1B1 was determined by Western blot using 
standard protocols. The primary monoclonal antibody mESL kindly 
provided by Prof. Dietrich Keppler, University of Heidelberg (Germany) 
(29) and a horse peroxidase (HRP)-conjugated secondary goat anti-
rabbit antibody (Sigma, Munich, Germany) were used. Visualization 
was achieved by enhanced chemoluminescence (SuperSignal 
Chemiluminescent-Substrate, Perbio-Science, Bonn, Germany).  
 
Flow cytometry analysis. Efficiency of cell transduction and GFP 
expression in hepatoma cells after transduction with Ad-GFP-NCRluc 
were measured by flow cytometry (Coulter Epics XL-Cytometer, 
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Immunotech, Krefeld, Germany). FITC-marked bile acid conjugated 
ODN served to analyze the cellular ODN uptake by flow cytometry. 
 
Adenoviral transduction of hepatoma cells and inhibition 
experiments. HepG2-OATP1B1, CCL13-OATP1B1 or Huh7 cells 
containing a HCV subgenomic replicon genotype 1b were seeded onto 
24-well plates and grown for 48 h. For experiments in HepG2-
OATP1B1  and CCL13-OATP1B1 cells, cells were transduced with Ad-
GFP-NCRluc with MOI 50 in DMEM supplemented with 2% horse 
serum for 2 h. Six hours after transduction, 2-6 µM ODN was added to 
the culture medium without any transfection reagent. For experiments 
with unconjugated ODN, ODN were mixed with 2 µl lipofectamine and 
200 µl Optimen and added to the cells for 24 h. For inhibition 
experiments in the Huh7 cells with the HCV replicon, 4 µM ODN was 
added to the culture medium.  
 
Imaging and quantification of bioluminescence. Animals were 
injected intravenously with the reporter vector Ad-GFP-NCRluc 
(5x107pfu/mouse). Luciferase was measured in vivo by live imaging 
using a highly sensitive, cooled charge-couple device camera (IVIS 200 
Xenogen, Alameda, CA, USA). For imaging, luciferin (Synchem, 
Alternburg, Germany) was injected intraperitonally at a dose of 150 
mg/kg body weight. After 5 min, light emitted from the mice was imaged 
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and electronically displayed using a Living Image Software (Xenogen, 
Ivis).  
 
Statistical analysis. For descriptive statistics, means and standard 
errors were noted. Paired t-test was used for statistical significance. A 
p-value of less than 0.05 was considered significant. 
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Results 
Inhibition of HCV translation by bile acid conjugated 
phosphorothioate ODN in vitro. 
Inhibitory activity of shortened phosphorothioate tS-ODN. 
The previously identified 23-base phosphorothioate modified 
oligonucleotide tS-ODN4 as potent inhibitor of HCV translation (10) 
was chosen for bile acid modification. To increase cell uptake of ODN 
after bile acid conjugation, we shortened the ODN sequence and 
generated several ODN derived from tS-ODN4 (s. Tab. 1). The effect of 
ODN length on their inhibitory potential was compared to the potent tS-
ODN4 in an in vitro transcription/translation assay. As shown in Fig. 2A, 
tS-ODN shortened to 20-17bp could still inhibit translation of the fusion 
HCV-RNA by >95%. With regard to the number of nucleotides, 17bp 
ODN (tS-ODN4_13) was the shortest sequence with the best inhibitory 
effect on the 5’NCR-dependent luciferase gene expression. This effect 
was HCV5’NCR-sequence specific, as the 17bp mismatch tS-
ODN4_13(K) could not inhibit HCV-translation (Fig. 2D). Therefore, for 
further bile acid conjugation, the 17mer tS-ODN was chosen as 
described in the methods. 
Further shortening of tS-ODN to 16-11bp resulted in lower inhibitory 
activity (<75%) and further shortening of ODN to 8bp in almost no 
inhibitory activity (<30%) (Fig 2B/C).  
Effect of bile acid conjugation on the inhibitory activity of tS-ODN4_13. 
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As shown in Fig. 3A, taurocholate (T), cholate (C) and cholesterol (X) 
conjugated antisense tS-ODN4_13 showed strong inhibition rates of 
5’NCR-dependent luciferase expression comparable to the inhibitions 
of unconjugated tS-ODN4_13 in vitro. Maximum suppression of HCV 
translation was achieved with the taurocholate conjugated ODN tS-
ODN4_13T. In this case, 4 µM tS-ODN4_13T reduced the luciferase 
activity by >90% (p<0.0001). Taurocholate tS-ODN4_13 was also the 
most effective bile conjugated ODN at the lowest concentration tested 
(0.5 µM), leading to an inhibition of almost 80% (p<0.0001). Contrary, 
cholate and cholesterol-coupled ODN (tS-ODN4_13C and tS-
ODN4_13X) reached maximum inhibition rates of 70% at 5 µM and no 
inhibitory effects at 0.5 µM.  
 
Inhibition of HCV gene expression by bile acid conjugated tS-
ODN4_13 in Huh7 cells containing a HCV subgenomic replicon.  
The inhibitory effects of taurocholate conjugated tS-ODN4_13 could not 
be reproduced properly in Huh7 cells containing a HCV subgenomic 
replicon of genotype 1b (Con1/Luc-ubi-neo/ET) since Huh7 cells have 
a down-regulation of bile acid transports. As expected, uptake of FITC-
marked tS-ODN4_13T was very low and correspondingly, almost no 
inhibitory effects were observed on HCV gene expression in this 
system (not shown). However, the cholesterol-coupled tS-ODN4_13X, 
which were highly incorporated by the Huh7 cells of the replicon 
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system (not shown) showed a significant inhibition of HCV translation 
of about 40% 48 h after ODN treatment compared to mismatch tS-
ODN4_13XK (p<0.0001) (Fig. 3B), demonstrating the inhibitory 
capacity of the chosen 17mer ODN sequence in the replicon system. 
 
Generation of OATP1B1 overexpressing hepatoma cells. 
In order to test the inhibitory potential of taurocholate coupled tS-
ODN4_13T in cell culture, the hepatoma cell lines HepG2 and CCL13 
were used. In these cells, a decreased expression of bile acid 
transporters, such as OATP, has been described compared to 
hepatocytes (30). Therefore, HepG2  and CCL13 cells were stably 
transfected to overexpress the OATP1B1 transporter. By RT-PCR, the 
transcription of OATP1B1 in HepG2 and CCL13 was verified as a 
strong amplification of a 490bp product compared to a very low or no 
expression in wild type HepG2 or CCL13 cells (Figs. 4A/B). By Western 
blot analysis, two bands of 84 kDa and 60 kDa in both OATP1B1 
overexpressing cell lines were detected (29), (Fig. 4C/D). The lower 
band corresponded to the core-glycosylated form of OATP1B1 (31). As 
expected, OATP1B1 was clearly reduced or not detectable in wild type 
HepG2  and CCL13 cells and no specific signal was detected in 911 
cells (negative control). 
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Construction and characterization of a NCRluc-encoding 
adenovirus vector. 
To quantify the inhibition of HCV translation by taurocholate conjugated 
antisense ODN in OATP-overexpressing HepG2  and CCL13 cells, we 
generated an adenovirus encoding HCV5’NCR fused to the luciferase 
gene as reporter vector (Ad-GFP-NCRluc) as described in methods. 48 
h after transduction of HepG2-OATP1B1  and CCL13-OATP1B1 cells 
with Ad-GFP-NCRluc, target-RNA (407bp) was confirmed by RT-PCR 
(Fig. 5A). The 5’NCR-dependent luciferase activity was dose-
dependent, reaching a peak 24 h after adenoviral transduction for all 
tested MOI (Figs. 5B/C).  
 
Inhibition of 5’NCR-dependent HCV gene expression by 
taurocholate conjugated phosphorothioate ODN in cell culture. 
Stably transfected HepG2-OATP1B1 and CCL13-OATP1B1 cells were 
transduced with Ad-GFP-NCRluc (MOI 50). Six hours later, 2-6 µM tS-
ODN4_13T was added to the cell supernatant without any transfection 
reagent. GFP expression served to normalize transgene luciferase 
expression. As shown in Figs. 6A/B, tS-ODN4_13T reduced luciferase 
activity in a dose-dependent manner reaching inhibition rates of 31.9+/-
0.9% with 2 µM ODN and 61.7+/-2.3% with 4 µM ODN in HepG2-
OATP1B1 compared to the mismatch control (p=0.032 and p=0.012, 
respectively). Addition of 6 µM ODN induced strong inhibition of 
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5’NCR-dependent translation of 70.6+/-4.9% compared to mismatch 
ODN (tS-ODN4_13TK), (p=0.0037). Similarly, in CCL13-OATP1B1 
cells, the maximum detected inhibition reached 57.4+/-0.45% 
(p=0.0042) 24 h after treatment with 6 µM tS-ODN4_13T.  
 
Inhibition of 5’NCR-dependent HCV gene expression by 
unconjugated tS-ODN4_13 in cell culture. 
In contrast, no significant inhibition of 5’NCR-dependent luciferase 
activity was detected after addition of unconjugated tS-ODN4_13 to the 
supernatant of OATP1B1-overexpressing HepG2  and CCL13 cells (not 
shown), indicating the OATP-selective cell delivery of taurocholate 
conjugated ODN in the previous experiment. When only a transfection 
reagent, such as lipofectamine, was applied, a moderate specific 
inhibition of HCV translation of approximately 35% with 4 µM tS-
ODN4_13 was observed in CCL13-OATP1B1 cells (p=0.018), (Fig. 
7B). In HepG2-OATP1B1 cells, despite the use of lipofectamine, no 
decrease of luciferase activity was detected (Figs. 7A).  
 
Intracellular uptake of taurocholate-conjugated ODN. 
To analyze intracellular uptake of taurocholate coupled ODN, FITC-
labeled tS-ODN4_13T were generated and used for flow cytometry. As 
shown in Figs. 8A/B, an about twice as high uptake of taurocholate 
conjugated tS-ODN4_13T was measured in OATP1B1-overexpressing 
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HepG2 cells (>90% of cells) compared to wild type HepG2 cells (only 
44% of cells). Moreover, intensity of fluorescence was approximately 
1log higher in HepG2-OATP1B1 cells than in HepG2 cells, also 
indicating an enhanced concentration of taurocholate conjugated 
ODN/cells. Surprisingly, FITC-non-conjugated ODN were also taken up 
by a relatively high percentage of HepG2-OATP1B1 cells (about 75%). 
Yet, intensity of fluorescence was much lower compared to 
taurocholate conjugated ODN, explaining the failure of inhibition of 
unconjugated ODN in HepG2 cells.  
As expected, taurocholate conjugated tS-ODN were not taken up by a 
number of tested non-hepatic human cell lines, such as A549 cells 
(lung carcinoma) or 911 cells (retinoblastoma), suggesting a selective 
delivery of taurocholate coupled tS-ODN into liver-derived cells (Fig. 
8C/D).  
It has been shown that certain non-hepatic tissues also possess 
transporters for bile acids, notably the kidney and the bowel. 
Correspondingly, an uptake of FITC-labeled taurocholate tS-ODN was 
detected in approximately 30% of HEK-293 cells (kidney-derived cells), 
and in about 35% of HT29-cells (colorectal adenocarcinoma cells) (Fig. 
8E/F). 
 
Inhibition of HCV gene expression by antisense bile acid 
conjugated ODN in vivo. 
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For in vivo evaluation of bile acid conjugated oligonucleotides tS-
ODN4_13T, we used the Ad encoding 5’NCR-luciferase fusion RNA 
(Ad-GFP-NCRluc). After intravenous (i.v.) application of Ad-GFP-
NCRluc (5x107 pfu/mouse), a high HCV luciferase expression could be 
tracked by whole body imaging bioluminescence in the liver of the 
mice. For inhibition experiments, mice were i.v.-treated with 20 mg 
ODN/kg body weight. As shown in Fig. 9, taurocholate coupled 
antisense tSODN showed a trend to higher inhibition of NCR-
dependent luciferase of about 40%, compared to mismatch ODN and 
unconjugated ODN.  
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Discussion 
In this study, we show that taurocholate conjugated antisense 
olignucleotides (ODN) complementary to the 5’NCR of the HCV 
genome allow selective ODN uptake into liver-derived cells and high 
specific inhibition of HCV translation in different test-systems indicating 
a novel strategy in the control of HCV infection. 
 
Design and testing of bile acid-coupled HCV-specific antisense ODN in 
vitro. 
The highly conserved 5’NCR of the HCV genome necessary for the 
HCV translation/replication has been shown to be an ideal target 
sequence for different antisense approaches, such as antisense RNA, 
RNA interference (RNAi), ribozymes or ODN (7-11). Phosphorothioate 
modified ODN are the first generation of antisense drugs entering 
clinical trials for the treatment of patients with chronic HCV infection 
which show acceptable properties for drug development (32). In the 
past, we reported that a 23-base phosphorothioate ODN (tS-ODN4) 
complementary to the nucleotides 326-348 of HCV5’NCR was highly 
efficient in reducing viral translation in vitro (10).  
However, a major limitation of the antisense technology - whether 
ODN, ribozymes or siRNA - is the specific tissue delivery. 
Phosphorothioate ODN are poorly incorporated into cells and usually a 
vehicle for tissue delivery is required. Several strategies, such as 
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liposomes, poly(ethylenglycol) (PEG)-conjugates, nanoparticles, 
electroporation, as well as cholesterol conjugates or cell-penetrating 
peptides, have been explored for tissue delivery of antisense 
molecules. However, these compounds either carry considerable 
cytotoxicity or their tissue specificity remains limited (13-16). 
Conjugation of drugs  as well as small peptide molecules and ODN by 
bile acid carriers has been described to augment uptake and selectivity 
of drug action, specifically in the liver (33, 34). Conjugation of a drug to 
a bile acid has also the theoretical advantage of improving delivery 
from the gut to the liver due to enterohepatic circulation. Moreover, bile 
acids appear to stabilize ODN against possible degradation (35). Thus, 
in this work, different bile acid conjugated phosphorothioate modified 
antisense ODN were generated and tested in order to achieve selective 
ODN uptake and more specific inhibition of HCV gene expression. 
Reduction of the number of nucleotides can favor uptake of ODN in 
hepatocytes after conjugation with bile acids, while at the same time, 
shortened ODN can lose their inhibitory efficacy. Therefore, in the first 
part of this work, we analyzed several shortened ODN derived from the 
20mer tS-ODN4 for their remaining antisense effects using an in vitro 
transcription/translation assay. Despite nucleotide reduction, a 17mer 
phosphorothioate modified ODN (tS-ODN4_13) complementary to nt 
342-326 of the HCV genome achieved almost a complete block of 
luciferase expression (95%) comparable to the parental tS-ODN4. This 
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effect was HCV sequence-specific, since the mismatch ODN (tS-
ODN4_13K) did not inhibit HCV translation. Further shortening of the 
20mer tS-ODN4 considerably reduced the inhibitory capacity of ODN, 
suggesting that inhibition of gene expression was dependent on the 
number of nucleotides which complementarily bind to the target 
sequence on the 5’NCR of HCV. The specific hybridisation of single-
stranded ODN to the complementary messenger RNA sequence by 
Watson-Crick base-pairing rules is a key mechanism of ODN blocking 
of the protein translation (36). Therefore, longer antisense sequences 
of nucleotides display increased nucleotide binding capacity and are 
more specific to its target, which explains the lower inhibitory effects of 
shortened ODN from tS-ODN4. 
The 17mer ODN, tS-ODN4_13, was the least effective inhibitory 
sequence and was therefore chosen for bile conjugation with cholate, 
taurocholate and cholesterol. Interestingly, while cholate and 
cholesterol conjugation reduced the inhibitory capacity of tS-ODN4_13, 
taurocholate conjugation exhibited no negative effects on the inhibitory 
capacity of the 17mer ODN reaching inhibition rates of >90% of HCV-
translation in vitro.  
 
Inhibition of bile acid-coupled HCV-specific antisense ODN in the HCV 
replicon system. 
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In the past, a system based on subgenomic HCV replicons capable to 
replicate in the hepatoma cell line Huh7 was developed (26). However, 
hepatoma cells are known to have a down-regulation of bile acid 
transports (29, 30). Correspondingly, FITC-marked taurocholate 
conjugated tS-ODN4_13 were not taken up by Huh7 cells, explaining 
the failed inhibition of HCV translation of tS-ODN4_13 in the replicon 
system. However, high uptake of cholesterol-coupled FITC-marked 
ODN by Huh7 cell with HCV replicons was noted, suggesting a non-
selective entrance of cholesterol ODN. Conjugation with cholesterol or 
other lipid moieties has been shown to enhance hepatic cell ODN 
uptake via lipoprotein-mediated endocytosis, explaining our results in 
the replicon system  (37, 38). Correspondingly, cholesterol-coupled tS-
ODN4_13X could moderately inhibit HCV gene expression in the HCV 
replicon system, indicating that the 17mer antisense sequence 
complementary to HCV5’NCR effectively inhibited HCV translation in 
the replicon system. 
 
Cell culture and in vivo HCV test systems. 
However, cholesterol-conjugated ODN showed less inhibitory capacity 
in the in vitro transcription/translation assay than taurocholate coupled 
ODN. Most importantly, as the goal of this work was to demonstrate a 
selective cell uptake of ODN due to bile acid transports experiments in 
cell lines with an adequate expression of bile acid transporters were 
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necessary to evaluate the efficiency of the potent taurocholate coupled 
ODN, tS-ODN4_13T.  
The organic anion transporting polypeptide (OATP) is a family of 
transport proteins responsible for transmembrane transport of diverse 
endogenous and exogenous compounds. In contrast to other OATP 
members localized in a variety of tissues (liver, kidney, brain and 
intestine) (30, 39), OATP1B1 has been found selectively in 
hepatocytes. It is the most important OATP for liver-specific bile salt 
uptake (17, 40). For this reason, OATP1B1 was chosen to generate 
stably transfected hepatoma cells. After stable transfection of HepG2 
and CCL13 with the OATP1B1-containing plasmid, an overexpression 
of OATP1B1 compared to the parental cell lines was observed.  
For completion of our cell culture test system, we generated an 
adenoviral vector (Ad-GFP-NCRluc) able to express the HCV-5’NCR 
sequence fused to the luciferase gene. For this fusion construct, we 
previously demonstrated that expression of luciferase is related to 
IRES activity of HCV5’NCR (10), providing a sensitive tool for 
quantification of the antisense effects related to HCV5’NCR. An 
adenoviral system offers a high transgene expression in hepatoma 
cells, allowing rapid screening and quantification of the 5’NCR-
dependent HCV gene expression in the generated OATP1B1-
overexpressing hepatoma cells. Moreover, an adenoviral system offers 
the possibility to evaluate inhibitions of the HCV5’NCR-related 
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luciferase expression in the liver of animal models after application of 
adenoviral vectors via the tail vein (8).  
 
Analysis of selective uptake of taurocholate conjugated tS-ODN in cell 
culture test system. 
To analyze the selective OATP1B1-dependent uptake of taurocholate 
conjugated ODN we generated FITC-labeled ODN. In contrast to 
earlier results of Petzinger et al. (35), we show that bile acid 
conjugation can deliver ODN to liver-derived cells via bile acid 
transport. In fact, uptake of taurocholate conjugated tS-ODN in 
OATP1B1-overexpressing HepG2 cells was found to be about twice as 
high than in wild type HepG2 cells with low or non-existent expression 
of bile acid transporters. Moreover, taurocholate conjugated tS-ODN 
were not taken up by non-hepatic cell lines, indicating selective entry of 
bile acid conjugated ODN only into liver-derived cells with enough bile 
acid transporter expression. The moderate uptake of taurocholate 
conjugated ODN found in wild type HepG2 cells, but also in HEK-293 
and HT29 cells, suggested contribution of other bile acid uptake 
transporters. Molecular evidence for the expression of both NTCP and 
different members of the OATP family in human hepatocellular 
carcinoma cells was found (30). Furthermore, OATP transporters are 
expressed in the gastrointestinal tract and in the kidney, explaining our 
observations in HEK293 and HT29 cells (41). 
M.A. González-Carmona et al., HCV antisense taurocholate conjugated ODN  31
 
Analysis of inhibition of HCV translation by taurocholate conjugated 
antisense ODN in cell culture test system and in vivo. 
Confirming our hypothesis, the increased uptake of taurocholate 
coupled ODN in OATP1B1-overexpressing hepatoma cells was 
translated into a higher and more efficient inhibition of the 5’NCRHCV-
dependent translation, reaching inhibition rates of >70%. The antisense 
inhibition was HCV sequence-specific  since the mismatch taurocholate 
coupled ODN did not inhibit HCV5’NCR-dependent luciferase 
expression. By contrast, no significant decrease of luciferase activity 
was observed with unconjugated antisense ODN when used without 
transfection reagent in HepG2-OATP1B1 cells and CCL13-OATP1B1 
cells. Taurocholate conjugation also provided a more efficient 
antisense effect on inhibiting HCV translation than use of traditional 
strategies, such as liposome-transfected ODN. In fact, even when 
using lipofectamine unconjugated ODN showed only moderate specific 
inhibition of HCV translation in CCL13 cells and no inhibition in HepG2 
cells.  
These findings are of importance because taurocholate conjugation of 
antisense ODN may overcome the problems derived from use of viral 
methods or invasive systems for delivering antisense molecules into 
the liver. As it can also be applied to other liver-related target genes it 
represents a novel approach for antisense based strategies.  
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In vivo, mice treated with taurocholate coupled antisense ODN also 
exhibited a trend towards less expression of the 5’NCR-dependent 
luciferase activity in the liver than mice treated with unmodified ODN, 
confirming the data in cell culture. However, standard deviations were 
high between the animals. This was probably due to a host immune 
response to viral proteins expressed by adenoviral vectors in vivo. 
Nevertheless, this experiment provided an important proof-of-concept, 
namely that taurocholate conjugated antisense ODN can also inhibit 
HCV5’NCR-dependent luciferase gene expression without apparent 
toxicities in vivo.  
In conclusion, we demonstrated that conjugation of ODN to bile acids 
such as taurocholate increases selective uptake of antisense ODN in 
bile acid transport expressing liver-derived cells. Taurocholate 
conjugated antisense ODN with sequences complementary to 
HCV5’NCR resulted in specific and effective inhibition of HCV gene 
expression. Thus, this approach may improve the use of antisense 
ODN into the liver and possibly represents a novel promising strategy 
for the control of hepatitis C virus infection.  
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Figure legends 
Figure 1 
A. 5´-bile acid and 3´-fluorescein modified antisense ODN (17mer) 
complementary to HCV5’NCR. 
B. Map of Ad-GFP-NCRluc with deletion of E1-, E3-genes, encoding 
two transgenes: the green fluorescent protein (GFP), and HCV5’NCR 
and 66 nt of core-sequence, fused to the firefly luciferase gene. LITR: 
left inverted terminal repeat, ES: encapsidation signal, CMV: 
cytomegalovirus immediate early promotor, MCS: multiple cloning site, 
Poly A: polyadenylation signal, Ad5ΔE1/ΔE3: human adenovirus type 5 
sequence with deletion of E1- and E3-genes, RITR: right inverted 
terminal repeat. 
 
Figure 2 Inhibitory activity of different shortened phosphorothioate 
modified ODN on HCV translation in an in vitro transcription/translation 
assay. All experiments were performed in triplicate. The percentage 
mean values and standard deviations are given.  
A. Inhibition rate of shortened antisense tS-ODN to 20mer , 
17mer  , 14mer   and 11mer  compared to 23mer tS-
ODN4  
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B. Inhibition rate of shortened antisense tS-ODN to 18mer          ,17mer 
 , 16mer   , to 15mer  and 14mer  compared to 
23mer tS-ODN4 , as control mismatch tS-ODN4K       
C. Inhibition rate of several shortened antisense tS-ODN to 8mer: tS-
ODN4_28  , tS-ODN4_30  , tS-ODN4_31  ,tS-
ODN4_33        and tS-ODN4_34  compared to 23mer tS-
ODN4 ,  mismatch ODN tS-ODN4K (as control) 
D. Inhibition rate of 17mer shortened ODN tS-ODN4_13  
compared to 23mer tS-ODN4 , as controls, mismatched ODN tS-
ODN4K        and tS-ODN4_13K         , were used. 
 
Figure 3  
A. Inhibitory activity of bile acid conjugated phosphorothioate modified 
antisense ODN on HCV-translation in an in vitro 
transcription/translation assay. Taurocholate , cholic acid  
and cholesterol  conjugated ODN compared to unconjugated tS-
ODN4_13 . Mismatch ODN tS-ODN4_13K (as control)  
B. Inhibitory activity of cholesterol phosphorothioate modified antisense 
tS-ODN4_13X (17mer) on HCV translation in Huh7 cell clone 
Con1/Luc-ubi-neo/ET containing the HCV subgenomic replicons of 
genotype 1b. Luciferase was measured 24 h and 48 h after ODN 
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treatment. Mean and SE are shown. Black bars: tS-ODN4_13 
(antisense); black bars: tS-ODN4_13K (mismatch). 
 
Figure 4 
A. Transcription of OATP1B1 confirmed by RT-PCR in HepG2-
OATP1B1 cells. Line 1: marker, line 2: OATP1B1 in 911 cells (control) 
line 3: OATP1B1 in wild type HepG2 cells, line 4: OATP1B1 in 
HepG2OATP1B1 cells (clone I), line 5: OATP1B1 in HepG2OATP1B1 
cells (clone II), line 6: OATP1B1 in HepG2OATP1B1 cells (clone III), 
line 7: beta actin in 911 cells, line 8: beta actin in wild type HepG2 cells, 
line 9: beta actin in HepG2OATP1B1 cells (clone I), line 10: beta actin 
in HepG2OATP1B1 cells (clone II), line 11: beta actin in 
HepG2OATP1B1 cells (clone III), line 12: OATP1B1 using plasmid 
pcDNA3.1/V5-HisOATP-C (positive control).  
B. Transcription of OATP1B1 confirmed by RT-PCR in CCL13-
OATP1B1 cells. Line 1: marker, line 2: OATP1B1 in 911 cells, line 3: 
OATP1B1 in CCL13OATP1B1 cells (clone A), line 4: OATP1B1 in 
CCL13OATP1B1 cells (clone B), line 5: OATP1B1 in wild type CCL13 
cells, line 6: beta actin in 911 cells, line 7: beta actin in 
CCL13OATP1B1 cells (clone A), line 8: beta actin in CCL13OATP1B1 
cells (clone B), line 9: beta actin in wild type CCL13 cells, line 10: 
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OATP1B1 using plasmid pcDNA3.1/V5-HisOATP-C (positive control). 
Only clone A was positive for OATP1B1.  
C. Expression of OATP1B1 confirmed by Western blot in stably 
transfected HepG2-OATP1B1 cells. Lines 1 and 2: OATP1B1 in wild 
type HepG2 cells. Line 3: OATP1B1 in HepG2OATP1B1 (clone I). Line 
4: OATP1B1 in HepG2OATP1B1 cells (clone II). Line 5 and 6:  
OATP1B1 in 911 cells (negative control).  
D. Expression of OATP1B1 confirmed by Western blot in stably 
transfected CCL13-OATP1B1 cells, lines 1 and 2: OATP1B1 in 
CCL13OATP1B1 (clone A); lines 3 and 4: OATP1B1 in CCL13 cells 
(wild type); lines 5 and 6: OATP1B1 in 911 cells (negative control).  
 
Figure 5 
A. Confirmation of transcription of target RNA (HCV5’NCR) in stable 
transfected hepatoma cells after adenoviral transduction with Ad-GFP-
NCRluc (MOI 50) by RT-PCR. Lines 1 and 7: marker; line 2: 
CCL13OATP1B1 cells; line 3: HepG2OATP1B1 cells, line 4: 
HepG2OATP1B1 using a second primer, line 5: plasmid 
pAdTrackCMVNCRluc, line 6: plasmid pCMVNCRluc (positive control). 
B. Kinetic of the luciferase expression in HepG2-OATP1B1 cells after 
adenoviral transduction with Ad-GFP-NCRluc at different MOIs.  
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C. Kinetic of luciferase expression in CCL13-OATP1B1 cells after 
adenoviral transduction with Ad-GFP-NCRluc at different MOIs.  
In both cases, luciferase activity was determined 8, 16, 24, 48 and 72 h 
after transduction with Ad-GFP-NCRluc: MOI 5  , MOI 25 , 
MOI 50 , MOI 100 , MOI 200 , (n=3).  
 
Figure 6 
A. Inhibition of HCV5’NCR-dependent luciferase gene expression in 
HepG2-OATP1B1 cells.  
B. Inhibition of HCV5’NCR-dependent luciferase gene expression in 
CCL13-OATP1B1 cells.  
To test the inhibitory potential of bile acid conjugated antisense tS-
ODN4_13T, 4x104 cells/well were seeded on a 24-well-plate. After 24 
h, cells were transduced with Ad-GFP-NCRluc at MOI 50. Six hours 
later, tS-ODN4_13T were added in different concentrations (2, 4 or 6 
µM) to the culture medium without any transfection reagent. Luciferase 
activity was determined 16, 24, 48 and 72 h later. As control, a 
mismatch antisense taurocholate conjugated ODN, tS-ODN4_13TK, 
was used. White bars: control ODN; black bars: antisense ODN. Mean 
and SE are shown (n=3). 
 
Figure 7 
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A. Inhibition of HCV5’NCR-dependent luciferase gene expression in 
HepG2-OATP1B1 cells using unconjugated antisense tS-ODN4_13. B. 
Inhibition of HCV5’NCR-dependent luciferase gene expression in 
CCL13-OATP1B1 cells using unconjugated antisense tS-ODN4_13. In 
both experiments, unconjugated tS-ODN4_13 were transfected using 
lipofectamine. Luciferase activity was determined 16, 24, 48 and 72 h 
later. White bars: mismatch tS-ODN4_13; black bars: antisense tS-
ODN4_13.  Mean and standard error are shown (n=3). 
 
Figure 8 
Selective uptake of FITC-labeled taurocholate conjugated tS-ODN in 
different cell lines was analyzed by flow cytometry. 2 µM of FITC-
labeled ODN was added to different cell types before flow cytometry 
was performed. A. Uptake of FITC-labeled ODN by HepG2 cells (wild 
type), B. by HepG2OATP1B cells, C. by A549 cells; D. by 911 cells; E. 
by HEK293 cells; F. by HT29 cells. 
 
Figure 9 
Inhibition of HCV5’NCR-dependent luciferase gene expression in vivo. 
5x107 pfu/mouse Ad-NCRluc was injected i.v.. Two hours later, 20 
mg/kg body weight ODN was injected i.v. Luciferase activity was 
determined 8, 24, 48 and 72 h later.  
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A. Inhibition experiments using unconjugated ODN: White bars: 
mismatch tS-ODN4_13K; black bars: antisense tS-ODN4_13 
B. Representative image of light emitted from two mice 24 h after i.v. 
injection of tS-ODN4_13K (left) or tS-ODN4_13 (right). 
C. Inhibition experiments using taurocholate conjugated ODN: White 
bars: mismatch tS-ODN4_13TK; black bars: antisense tS-ODN4_13T 
D. Representative image of light emitted from two mice 24 h after i.v. 
injection of tS-ODN4_13TK (left) or tS-ODN4_13T (right). 
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